ANI Pharma (ANIP) Tops Q3 EPS by 26c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.34, $0.26 better than the analyst estimate of $1.08. Revenue for the quarter came in at $148.3 million versus the consensus estimate of $143.98 million.

GUIDANCE:

ANI Pharma sees FY2024 EPS of $4.90-$5.05, versus the consensus of $4.72. ANI Pharma sees FY2024 revenue of $594-602 million, versus the consensus of $590.3 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• List of suppliers, parts, photos of iPhone 18 Pro are part of Tata Electronics data breach - Reuters
• Iran's foreign ministry spokesperson: no talks with the U.S. in coming days
• LifeStance Health Group, Inc. (LFST) call put ratio 11.6 calls to 1 put with a focus on 4K contracts of August 12 calls